Literature DB >> 31403864

Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.

Andreas du Bois1, Thaïs Baert1,2, Ignace Vergote2,3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31403864     DOI： 10.1200/JCO.19.00022

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

Review 1.  Low-grade Serous Tumors: Are We Making Progress?

Authors:  Nina Pauly; Sarah Ehmann; Enzo Ricciardi; Beyhan Ataseven; Mareike Bommert; Florian Heitz; Sonia Prader; Stephanie Schneider; Andreas du Bois; Philipp Harter; Thaïs Baert
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

2.  Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients.

Authors:  Jan Philipp Ramspott; Thaïs Baert; Michelle Louise MacKintosh; Alexander Traut; Beyhan Ataseven; Mareike Bommert; Florian Heitz; Helmut Plett; Stephanie Schneider; Kai-Uwe Waltering; Sebastian Heikaus; Philipp Harter; Andreas du Bois
Journal:  Arch Gynecol Obstet       Date:  2021-03-04       Impact factor: 2.344

3.  Expression of CD44+/CD24-, RAD6 and DDB2 on chemotherapy response in ovarian Cancer: A prospective flow cytometry study.

Authors:  Unedo Hence Markus Sihombing; Gatot Purwoto; Supriadi Gandamihardja; Alida R Harahap; Primariadewi Rustamadji; Aria Kekalih; Retno Widyawati; Dzicky Rifqi Fuady
Journal:  Gynecol Oncol Rep       Date:  2022-06-03

4.  Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.

Authors:  Yasmin A Lyons; Henry D Reyes; Megan E McDonald; Andreea Newtson; Eric Devor; David P Bender; Michael J Goodheart; Jesus Gonzalez Bosquet
Journal:  Int J Gynecol Cancer       Date:  2020-04-26       Impact factor: 3.437

5.  Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study.

Authors:  Ann Vankerckhoven; Roxanne Wouters; Thomas Mathivet; Jolien Ceusters; Thaïs Baert; Anaïs Van Hoylandt; Holger Gerhardt; Ignace Vergote; An Coosemans
Journal:  Cells       Date:  2020-01-27       Impact factor: 6.600

Review 6.  Dose-Intense Cisplatin-Based Neoadjuvant Chemotherapy Increases Survival in Advanced Cervical Cancer: An Up-to-Date Meta-Analysis.

Authors:  Van Tai Nguyen; Sabine Winterman; Margot Playe; Amélie Benbara; Laurent Zelek; Frédéric Pamoukdjian; Guilhem Bousquet
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

7.  Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression.

Authors:  Jun Li; Huiran Yue; Wenzhi Li; Guohua Zhu; Tingting Zhu; Ruifang Chen; Xin Lu
Journal:  J Ovarian Res       Date:  2021-11-22       Impact factor: 4.234

8.  Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer.

Authors:  Jieun Ko; Hyeong In Ha; Min Chul Choi; Sang Geun Jung; Hyun Park; Won Duk Joo; Seung Hun Song; Chan Lee; Joon Mo Lee
Journal:  Obstet Gynecol Sci       Date:  2021-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.